11 May, '2026
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain
05 May, '2026
Q1 2026 net revenues increased 10.0%, or 6.5% on a co nstant currenc y basis, compared to Q1 2025 Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025 Q1 2026 Adjusted EBITDA ( 1) increased 10.5%, or 6.9% on a
05 May, '2026
Alton Shader, CEO of Viant Medical ®, to become CEO and join the Board of Directors, effective May 26, 2026 Chairman and CEO Michael B. Petras, Jr. will serve as Executive Chairman of the Board of Directors CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the
21 Apr, '2026
CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the
16 Mar, '2026
CLEVELAND, March 16, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company” or “Sotera Health”), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today that it has
04 Mar, '2026
CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25 million shares of its common stock, par value $0.01 per share. All 25 million shares are being offered for sale by certain
24 Feb, '2026
2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis 2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 2024 2025 Adjusted EBITDA (1) increased 8.2% to $594
17 Feb, '2026
CLEVELAND, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the
05 Feb, '2026
CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G.
12 Jan, '2026
CLEVELAND, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, is presenting today at the 44th